Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Share-based Compensation (2020 - 2025)

Historic Share-based Compensation for TScan Therapeutics (TCRX) over the last 6 years, with Q3 2025 value amounting to $3.0 million.

  • TScan Therapeutics' Share-based Compensation rose 1934.21% to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.4 million, marking a year-over-year increase of 4891.42%. This contributed to the annual value of $9.5 million for FY2024, which is 8335.25% up from last year.
  • Latest data reveals that TScan Therapeutics reported Share-based Compensation of $3.0 million as of Q3 2025, which was up 1934.21% from $3.3 million recorded in Q2 2025.
  • In the past 5 years, TScan Therapeutics' Share-based Compensation registered a high of $3.4 million during Q1 2025, and its lowest value of $344000.0 during Q1 2021.
  • Over the past 5 years, TScan Therapeutics' median Share-based Compensation value was $1.3 million (recorded in 2022), while the average stood at $1.7 million.
  • Per our database at Business Quant, TScan Therapeutics' Share-based Compensation surged by 59140.62% in 2021 and then skyrocketed by 762.44% in 2023.
  • TScan Therapeutics' Share-based Compensation (Quarter) stood at $784000.0 in 2021, then surged by 65.43% to $1.3 million in 2022, then increased by 15.65% to $1.5 million in 2023, then skyrocketed by 80.93% to $2.7 million in 2024, then rose by 10.94% to $3.0 million in 2025.
  • Its Share-based Compensation stands at $3.0 million for Q3 2025, versus $3.3 million for Q2 2025 and $3.4 million for Q1 2025.